Literature DB >> 24647918

Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer.

Tao Bai1, Dao-Song Dong1, Ling Pei1.   

Abstract

MicroRNAs have emerged as promising molecular factors with potential for clinical applications in cancer diagnosis and therapy. In the present study, we demonstrated that the level of miR-200c in lung cancer tissues was lower than that in normal tissues using real-time PCR. To further investigate the effects of miR-200c expression in lung cancer cells, we upregulated miR-200c levels in H460 cells using transfection. We found that the percentage of apoptotic cells was higher in the cells expressing miR-200c than that in the untransfected cells. Furthermore, the antitumor activities of miR-200c were demonstrated in vivo. Notably, we confirmed that reservatol (RESV) showed stronger antitumor activities in miR-200c-positive cells than in miR-200c-negative cells. Finally, we demonstrated that expression of miR-200c in H460 cells suppressed cell growth by targeting RECK, followed by activation of the JNK signaling pathway and ER stress. Collectively, these data show that miR-200c expression sensitizes H460 cells to RESV and this is likely due to RECK expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647918     DOI: 10.3892/or.2014.3090

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer.

Authors:  Libo Si; Hui Tian; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Lei Qi
Journal:  Oncol Lett       Date:  2017-07-25       Impact factor: 2.967

Review 2.  Modulation of microRNAs by phytochemicals in cancer: underlying mechanisms and translational significance.

Authors:  Sanjeev K Srivastava; Sumit Arora; Courey Averett; Seema Singh; Ajay P Singh
Journal:  Biomed Res Int       Date:  2015-03-17       Impact factor: 3.411

Review 3.  Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.

Authors:  Thomas K Sin; Fengfeng Wang; Fei Meng; S C Cesar Wong; William C S Cho; Parco M Siu; Lawrence W C Chan; Benjamin Y M Yung
Journal:  Int J Mol Sci       Date:  2016-02-15       Impact factor: 5.923

Review 4.  Resveratrol as a potential therapeutic drug for respiratory system diseases.

Authors:  Xiao-Dan Zhu; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Drug Des Devel Ther       Date:  2017-12-15       Impact factor: 4.162

5.  MicroRNA 200c-3p regulates autophagy via upregulation of endoplasmic reticulum stress in PC-3 cells.

Authors:  Eun Jung Sohn
Journal:  Cancer Cell Int       Date:  2018-01-03       Impact factor: 5.722

Review 6.  HDAC Inhibitors and RECK Modulate Endoplasmic Reticulum Stress in Tumor Cells.

Authors:  Yun Chen; Ya-Hui Tsai; Sheng-Hong Tseng
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

7.  Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation Deficiency.

Authors:  Virginie Aires; Dominique Delmas; Fatima Djouadi; Jean Bastin; Mustapha Cherkaoui-Malki; Norbert Latruffe
Journal:  Molecules       Date:  2017-12-22       Impact factor: 4.411

Review 8.  Resveratrol: A Potential Hippocampal Plasticity Enhancer.

Authors:  Gisele Pereira Dias; Graham Cocks; Mário Cesar do Nascimento Bevilaqua; Antonio Egidio Nardi; Sandrine Thuret
Journal:  Oxid Med Cell Longev       Date:  2016-05-25       Impact factor: 6.543

9.  MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK.

Authors:  Yidong Cheng; Xiaolei Zhang; Peng Li; Chengdi Yang; Jinyuan Tang; Xiaheng Deng; Xiao Yang; Jun Tao; Qiang Lu; Pengchao Li
Journal:  Onco Targets Ther       Date:  2016-08-16       Impact factor: 4.147

10.  Negative Correlation between miR-200c and Decorin Plays an Important Role in the Pathogenesis of Colorectal Carcinoma.

Authors:  Ren-Yi Tang; Zun Wang; Hong-Qi Chen; Si-Bo Zhu
Journal:  Biomed Res Int       Date:  2017-04-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.